Summary News Back
Rising awareness and media coverage of liver diseases, particularly PBC, including expert discussions and patient stories on various platforms.
Promising clinical trial results for new PBC treatments such as linerixibat, seladelpar (Livdelzi), and elafibranor (Iqirvo), showing improvements in symptoms like itch and fatigue.
Regulatory progress with multiple approvals and conditional authorizations of PBC treatments across Europe, the US, and the UK (e.g., Livdelzi, Iqirvo).
Ongoing research into the mechanisms and associated conditions of PBC, including links to lymphoma, systemic sclerosis, and gut microbiota.
Growing investment and milestone payments in the PBC drug development sector, reflecting commercial interest and expanding treatment options.
Studies highlighting the importance of early diagnosis, personalized treatment plans, and quality of life improvements for PBC patients.
Concerns over safety and effectiveness of existing treatments, with regulatory bodies declining or revoking approvals (e.g., Ocaliva).
Educational efforts through art, patient stories, and physician guidance to support awareness and understanding of rare liver diseases like PBC.
News Articles Back
16/03/2026 The secretory protein, CLCF1, improves cholestatic liver disease by inhibiting hepatic bile acid synthesis and promoting bile acid excretion - Nature
12/03/2026 Former News 12 reporter Amy McGorry searching for living liver donor - News12 | Long Island
10/03/2026 AIFA approves reimbursement for seladelpar for primary biliary cholangitis - lamilano.it
09/03/2026 GSK licenses liver disease drug to Italy's Alfasigma for up to $690 million - Reuters
09/03/2026 Italy's Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision - Fierce Biotech
11/02/2026 Primary biliary cholangitis–associated osteoporosis: contemporary review of pathogenesis and management - EurekAlert!
14/01/2026 Diagnostic potential of salivary biomarkers for primary biliary cholangitis: a systematic review - Frontiers
02/01/2026 Seladelpar reduced pruritus in PBC as early as ‘first month, and persisted’ - Healio
23/12/2025 Vitamin D3 attenuates hepatic inflammation in primary biliary cholangitis by inhibiting TLR4/NF-κB mediated M1 macrophage polarization | Scientific Reports - Nature
22/12/2025 Treating primary biliary cholangitis - mcpress.mayoclinic.org
11/12/2025 After Being Pulled from the Market, Liver Drug Ocaliva Could Soon Face Lawsuits - Drugwatch.com
03/12/2025 Shifts in Blood Lipids Linked to Early Primary Biliary Cholangitis - European Medical Journal
27/11/2025 Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation - Nature
21/11/2025 Patients with Primary Biliary Cholangitis Miss Recommended Monitoring - European Medical Journal
20/11/2025 VIDEO: Iqirvo may stabilize primary biliary cholangitis progression after long-term use - Healio
19/11/2025 Blood group A linked to a higher risk of primary biliary cholangitis - News-Medical
18/11/2025 Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR Agonists & Immunomodulators | DataM Intelligence - Yahoo Finance
12/11/2025 VIDEO: Livdelzi demonstrates benefit in PBC regardless of prior fibrate, OCA use - Healio
10/11/2025 Seladelpar Staves Off Liver Stiffness in PBC - Medscape
10/11/2025 Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression - BioSpace
30/10/2025 Seladelpar’s Impact on Pruritus in Primary Biliary Cholangitis, With Marlyn Mayo, MD - HCPLive
30/10/2025 Elafibranor More Cost-Effective Than Seladelpar for Second-Line PBC Treatment - HCPLive
29/10/2025 Liver Drug Approval and Pipeline Data Could Be a Game Changer for Gilead Sciences (GILD) - Yahoo Finance
27/10/2025 Exploring primary biliary cholangitis - Healio
26/10/2025 Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies - Baishideng Publishing Group
21/10/2025 LYVDELZI® RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - Investing News Network
14/10/2025 Primary biliary cholangitis. Treatment options in 2025. A narrative review - Frontiers
14/10/2025 Multi-omics tests identify novel shared genetic mechanisms of primary biliary cholestasis and sarcopenia - Nature
10/10/2025 Bezafibrate for primary biliary cholangitis: time to act on the evidence - Nature
09/10/2025 Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary Cholangitis - Cureus
08/10/2025 The role of mitochondria-related key genes in primary biliary cholangitis was analyzed based on transcriptome sequencing data - Frontiers
19/09/2025 Mixed Multiple Autoimmune Syndrome Type 3 With Coexistence of Primary Biliary Cholangitis, Inflammatory Myopathy, and Chronic Thyroiditis: A Case Report - Cureus
15/09/2025 Common pathological mechanisms and therapeutic strategies in primary Sjogren’s syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy - Frontiers
12/09/2025 Intercept withdraws Ocaliva for PBC from the US market - The Pharmaletter
11/09/2025 Ocaliva for Primary Biliary Cholangitis Withdrawn From US Market - Medscape
11/09/2025 Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold - Yahoo Finance
10/09/2025 Gilead fashions new primary biliary cholangitis campaign alongside 'Project Runway' designer - Fierce Pharma
05/09/2025 Innate immunity of bile and cholangiocytes in primary biliary cholangitis - Frontiers
27/08/2025 Local Woman Launches Support Group For People With Primary Biliary Cholangitis - The Citizen Newspaper Group
26/08/2025 Pruritus Increases HRQoL Burden in PBC, Underscoring Need for Effective Treatments - HCPLive
03/08/2025 Research progress and perspectives of non-coding RNAs in primary biliary cholangitis: from mechanisms to therapeutics - Frontiers
23/07/2025 PPAR agonists effective in UDCA-resistant primary biliary cholangitis - Liver Disease News
08/07/2025 Fulminant Primary Biliary Cholangitis-Autoimmune Hepatitis (PBC-AIH) Overlap Syndrome in a 27-Year-Old Woman With Childhood-Onset AIH: Steroid-Refractory Decompensation Necessitating Urgent Transplant Evaluation - Cureus
02/07/2025 Endothelial cells expressing CPE and vWF are involved in the Immunopathogenesis of primary biliary cholangitis - Nature
30/06/2025 Treatment of pruritus in primary biliary cholangitis - Clínica FEHV
25/06/2025 EMA to review linerixibat for primary biliary cholangitis-related itch - Liver Disease News
20/06/2025 Novel Therapies for Primary Biliary Cholangitis - Medscape
12/06/2025 Primary biliary cholangitis and the narrowing gap towards optimal disease control - The Lancet
11/06/2025 T and B cell responses against Epstein–Barr virus in primary sclerosing cholangitis - Nature
22/05/2025 New Kids on the Block: Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis - European Medical Journal
19/05/2025 Double Trouble: Drug-Induced Autoimmune Hepatitis (AIH)-Primary Biliary Cholangitis (PBC) Overlap Syndrome Triggered by Hydralazine - Cureus
14/05/2025 Livdelzi effective on primary biliary cholangitis, regardless of prior treatment - Liver Disease News
09/05/2025 Gilead’s Livdelzi Shows Lasting Efficacy in Primary Biliary Cholangitis, Regardless of Prior Therapy - Pharmaceutical Executive
08/05/2025 Iqirvo Shows Significant Fatigue Improvement in Patients with Primary Biliary Cholangitis After 52 Weeks in Phase III ELATIVE Trial - Applied Clinical Trials
07/05/2025 Bringing PBC Into Focus Through Art of Patient Stories - Gilead Sciences
28/04/2025 Health Canada approves IQIRVO® as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis - Ipsen
23/04/2025 90% of People With This Rare Liver Disease Are Women—Meet the Patient Advocate Helping Empower Others - Flow Space
10/04/2025 Systemic Sclerosis and Primary Biliary Cholangitis: A Comprehensive Review of Two Overlapping Rare Entities With Insights on Diagnostics and Management - Cureus
09/04/2025 Scotland's NHS to cover Iqirvo for eligible adults with primary biliary cholangitis - Liver Disease News
08/04/2025 Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis - PMLiVE
04/04/2025 Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap in a Case of Pulmonary Arterial Hypertension and Sjögren's Syndrome: Occam's Razor or Hickam's Dictum? - Cureus
03/04/2025 Fatigue and itch severity in patients with PBC and PSC: Prospective analysis of two large cohorts - Wiley Online Library
07/03/2025 Autoimmune Gastritis Complicated by Primary Biliary Cholangitis: A Report of Two Cases and Literature Review - Cureus
24/02/2025 Breaking Grounds: A Comprehensive Analysis of Cutting-Edge Treatments for Primary Biliary Cirrhosis/Primary Biliary Cholangitis With Futuristic Treatments - Cureus
06/01/2025 A Rare Case of Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome in a Male Patient - Cureus
02/01/2025 Serious liver injury being observed in patients without cirrhosis taki - fda.gov
28/12/2024 Development and external validation of an early prediction model to identify irresponsive patients and prognosis of UDCA treatment in primary biliary cholangitis - Nature
26/11/2024 Answering Common Questions About Primary Biliary Cholangitis - Cleveland Clinic Health Essentials
16/11/2024 Bidirectional Mendelian randomization links gut microbiota to primary biliary cholangitis - Nature
13/11/2024 Primary biliary cholangitis: Your guide to diet and nutrition - mcpress.mayoclinic.org
13/11/2024 Primary biliary cholangitis: What does successful treatment look like? - mcpress.mayoclinic.org
10/10/2024 Drug rivals face off in PBC after FDA hands down 2 new approvals, 1 advisory snub - Healio
07/10/2024 Single-cell RNA sequencing reveals the pro-inflammatory roles of liver-resident Th1-like cells in primary biliary cholangitis - Nature
04/07/2024 A Case of Primary Biliary Cholangitis in a Patient With Multiple Sclerosis - Cureus
25/06/2024 The overlap with metabolic dysfunction-associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis - Wiley Online Library
19/06/2024 Long-term outcomes in patients with primary biliary cholangitis complicated with CREST syndrome - Nature
04/06/2024 Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease - American Physiological Society Journal
21/05/2024 Dissecting causal relationships between primary biliary cholangitis and extrahepatic autoimmune diseases based on Mendelian randomization - Nature
20/05/2024 Exploring life and parenthood with Primary Biliary Cholangitis - Ipsen
05/03/2024 Constitutive Activation of Natural Killer Cells in Primary Biliary Cholangitis - Frontiers
21/02/2024 A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis | New England Journal of Medicine - The New England Journal of Medicine
21/02/2024 PPAR Agonists in Primary Biliary Cholangitis - The New England Journal of Medicine
15/02/2024 Gut microbial profile of treatment-naive patients with primary biliary cholangitis - Frontiers
11/02/2024 Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis? - Frontiers
11/02/2024 Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study - Frontiers
10/02/2024 Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products - Frontiers
05/02/2024 New insights on the role of human leukocyte antigen complex in primary biliary cholangitis - Frontiers
28/11/2023 Primary Biliary Cholangitis: The Power of Patient Reported Outcomes - Ipsen
16/11/2023 Clinical trial results suggest potential new treatment for primary biliary cholangitis - University of California - Davis Health
13/11/2023 Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis | New England Journal of Medicine - The New England Journal of Medicine
31/10/2023 Innovating for people living with primary biliary cholangitis - Ipsen
31/08/2023 Life with Primary Biliary Cholangitis: Sabrina’s Story - Ipsen
06/07/2023 Causal associations between inflammatory bowel disease and primary biliary cholangitis: a two-sample bidirectional Mendelian randomization study | Scientific Reports - Nature
09/02/2023 small cholangiocytes are pathogenic targets for primary biliary cholangitis - Nature
12/11/2022 Hyperlipidemia in the Setting of Primary Biliary Cholangitis: A Case Report and Review of Management Strategies - Cureus
01/12/2021 Primary Biliary Cholangitis - American Liver Foundation
09/12/2019 Primary biliary cholangitis: pathogenesis and therapeutic opportunities - Nature
08/08/2019 Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort - Nature
06/06/2018 A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis - The New England Journal of Medicine
18/08/2016 A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis - The New England Journal of Medicine
